Riskpilot← Back to searchSign inGet full accessBioperm Aktiebolag
ABActiveOrg 5564268497Tullgatan 1 AHospital activities · NACE 8610Est. 19911 employees
Revenue 2025
SEK 0
EBITDA margin
—
+90% vs 2024
Equity ratio
95.9%
Financial strength
Net profit 2025
SEK -32K
+59% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | +90% |
| Net profit | SEK -32K | +59% |
| Total assets | SEK 5,1M | -6% |
| Equity | SEK 4,9M | -5% |
| Employees | 1 | — |
Legal name
Bioperm Aktiebolag
Org number
5564268497
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
24 maj 1991
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Månsson, Carl Jakob Börje Månsson, Gertrud Elisabet Åsa Månsson, Karl Gunnar Viking
Company purpose
Bolaget skall bedriva forskning, inkluderande uppdragsforskning och produktutveckling inom det medicinska och det medicintekniska området, samt idka utbildning och klinisk medicinsk verksamhet.
Address
Tullgatan 1 A
Email
wiking.mansson@bioperm.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 376 | 0 | 0 | 0 | 0 |
| Staff expenses | — | −121 | −140 | −0 | — |
| EBITDA | 1 047 | −259 | −272 | −81 | −8 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 1 047 | −259 | −272 | −81 | −8 |
| Net financials | −11 | −52 | 85 | 14 | −21 |
| Profit before tax | 1 036 | −1 | 404 | −67 | −29 |
| Tax | −216 | −14 | −83 | −11 | −3 |
| Net profit | 820 | −16 | 321 | −77 | −32 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 850 | 6 004 | 5 630 | 5 399 | 5 090 |
| Equity | 5 477 | 5 273 | 5 406 | 5 124 | 4 883 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 373 | 41 | 124 | 175 | 107 |
| Total debt | 373 | 41 | 124 | 175 | 107 |
EBITDA margin
-819300.0%
This company
15.8%
Market median
-5185543% vs market
20212025
Equity ratio
95.9%
This company
38.2%
Market median
+151% vs market
20212025
Return on equity
-0.7%
This company
18.4%
Market median
-104% vs market
20212025
Net profit margin
-3191400.0%
This company
8.1%
Market median
-39400100% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
KG Chief Executive Officer | Chief Executive Officer | 2022 |
GE Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioperm Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Gunnar Viking Månsson | Chief Executive Officer | 0 companies |
| Gertrud Elisabet Åsa Månsson | Chief Executive Officer | 0 companies |
| Carl Jakob Börje Månsson | Deputy Board Member | 0 companies |